Indacaterol 300 μg
Sponsors
Novartis, Novartis Pharmaceuticals
Conditions
AsthmaChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)
Phase 2
Phase 3
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
CompletedNCT00529529
Start: 2007-09-30End: 2008-08-31Updated: 2011-08-29
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
CompletedNCT00620022
Start: 2008-04-30End: 2009-01-31Updated: 2011-08-17
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00622635
Start: 2008-01-31End: 2008-07-31Updated: 2011-08-18
Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT00792805
Start: 2008-11-30End: 2010-02-28Updated: 2011-08-17